VERU
Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility and novel chemotherapies for a variety of cancers.
Veru Inc. (VERU) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C+ (2.5) | D+ (1.5) | B- (2.9) | C+ (2.8) | C+ (2.6) | C (2.5) |
| 2026-11-08 | C+ (2.5) | D+ (1.5) | B- (2.9) | C+ (2.6) | C+ (2.6) | C (2.4) |
| 2026-11-01 | C+ (2.5) | D+ (1.5) | B- (2.9) | B- (2.9) | C+ (2.7) | C+ (2.5) |
| 2026-10-25 | C+ (2.5) | D+ (1.5) | B- (2.9) | C+ (2.6) | C+ (2.6) | C (2.4) |
| 2026-10-18 | C+ (2.5) | D+ (1.5) | B- (2.9) | C+ (2.5) | C+ (2.6) | C (2.4) |